ebastine has been researched along with Chronic Disease in 3 studies
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ebastine is a new second generation histamine H1 receptor antagonist that has shown clinical efficacy in the treatment of seasonal and perennial allergic rhinitis and chronic urticaria after once-daily administration." | 9.08 | Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. ( Kalis, B, 1996) |
| "Ebastine is a second-generation antihistamine which has been shown to be an effective treatment for both seasonal and perennial allergic rhinitis." | 6.44 | Ebastine in allergic rhinitis and chronic idiopathic urticaria. ( Sastre, J, 2008) |
| " Pruritus, number, diameter, duration and frequency of wheals, and adverse reactions were assessed." | 5.72 | Efficacy and safety of ebastine dose escalation in chronic urticaria: A prospective study. ( Chen, Q; Hao, F; Li, S; Qian, T; Song, Z; Zhang, D, 2022) |
| "Ebastine is a new second generation histamine H1 receptor antagonist that has shown clinical efficacy in the treatment of seasonal and perennial allergic rhinitis and chronic urticaria after once-daily administration." | 5.08 | Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. ( Kalis, B, 1996) |
| "Ebastine is a second-generation antihistamine which has been shown to be an effective treatment for both seasonal and perennial allergic rhinitis." | 2.44 | Ebastine in allergic rhinitis and chronic idiopathic urticaria. ( Sastre, J, 2008) |
| " Pruritus, number, diameter, duration and frequency of wheals, and adverse reactions were assessed." | 1.72 | Efficacy and safety of ebastine dose escalation in chronic urticaria: A prospective study. ( Chen, Q; Hao, F; Li, S; Qian, T; Song, Z; Zhang, D, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Qian, T | 1 |
| Li, S | 1 |
| Chen, Q | 1 |
| Zhang, D | 1 |
| Song, Z | 1 |
| Hao, F | 1 |
| Sastre, J | 1 |
| Kalis, B | 1 |
1 review available for ebastine and Chronic Disease
| Article | Year |
|---|---|
Ebastine in allergic rhinitis and chronic idiopathic urticaria.
Topics: Animals; Butyrophenones; Chronic Disease; Histamine H1 Antagonists; Humans; Piperidines; Rhinitis, A | 2008 |
1 trial available for ebastine and Chronic Disease
| Article | Year |
|---|---|
Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults.
Topics: Adult; Anti-Allergic Agents; Butyrophenones; Chronic Disease; Double-Blind Method; Histamine H1 Anta | 1996 |
1 other study available for ebastine and Chronic Disease
| Article | Year |
|---|---|
Efficacy and safety of ebastine dose escalation in chronic urticaria: A prospective study.
Topics: Butyrophenones; Cholinergic Agents; Chronic Disease; Chronic Urticaria; Headache; Histamine H1 Antag | 2022 |